Amgen Inc. (AMGN) Q1 2026 Earnings Call

Investor webinar replay

Replay transcript excerpt

My name is Julianne and I will be your conference facilitator today for the Amgen Q1 twenty twenty six Earnings Conference Call. All lines have been placed on mute to prevent any background noise. There will be a question and answer session at the conclusion of the last speaker's prepared remarks. In order to ensure that everyone has a chance to participate, we would like to request that you limit yourself to asking one question during the Q and A session. To ask a question, please press star then the number one on your telephone keypad. To withdraw your question, please press star one again. I would now like to introduce Casey Caporelli, Vice President of Investor Relations. Mr. Caporelli, may now begin. Thank you, Julianne. Good afternoon, everyone, and welcome to our first quarter of twenty twenty six earnings call. Bob Bradway will lead the call today and be followed by a broader review of our performance by Myrtle Gordon, Jay Bradner, and Peter Griffith. Through the course of our discussion today we will use non GAAP financial measures to describe our performance and have provided appropriate reconciliations within the materials that accompany this call. We will also make some forward looking statements which are qualified by our safe harbor statement. And please note that actual results can vary materially. Over to you, Bob. Okay, good afternoon and thank you for joining us. We had a strong first quarter and are well positioned to achieve our objectives for the year. Recall, we previously described 2026 as a springboard year for Amgen, a year in which we expect our rapidly growing products to offset the financial impact of patent expirations and increased competition, while our next generation of molecules progress through the R and D pipeline, setting the stag...